Skip to main content
SpringerLink
Log in

Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral chemotherapy has become a major component of the treatment of advanced prostate cancer. The recognition that prostate cancer grows very slowly and must be treated continuously with active agents has led to the development of several therapeutic regimens. These regimens employ oral agents such as estramustine, cyclophosphamide, and etoposide, as they can be taken on a daily basis at home by the patients. These regimens have demonstrated activity in patients with hormone-refractory prostate cancer; declines in both prostate specific antigen and soft tissue lesions have been demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5–27

    Article  PubMed  CAS  Google Scholar 

  2. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Can Res 1995; 1: 473–80

    CAS  Google Scholar 

  3. Isaacs JT. Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat prostatic adenocarcinomas. Cancer Res 1982; 42: 5010–4

    PubMed  CAS  Google Scholar 

  4. Eisenberger MA. Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7: 151–63

    PubMed  Google Scholar 

  5. Murphy GP, Slack NH, Mittelman A. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology 1984; 23: 54–63

    Article  PubMed  CAS  Google Scholar 

  6. Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986; 9: 387–95

    Article  PubMed  CAS  Google Scholar 

  7. Nelson WG, Pienta KJ, Barrack ER, et al. The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem 1986; 15: 457–75

    Article  PubMed  CAS  Google Scholar 

  8. Ciejek EM, Tsai M, O’Malley BW. Actively transcribed genes are associated with the nuclear matrix. Nature 1983; 306: 607–9

    Article  PubMed  CAS  Google Scholar 

  9. Hussain MH, Pienta KJ, Redman BG, et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994; 74: 100–3

    Article  PubMed  CAS  Google Scholar 

  10. Walther PJ, Williams SD, Troner M, et al. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 1986; 70: 771–2

    PubMed  CAS  Google Scholar 

  11. Scher HI, Sternberg C, Heston WD, et al. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemother Pharmacol 1986; 18: 24–6

    Article  PubMed  CAS  Google Scholar 

  12. Nelson WG, Liu LF, Coffey DS. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 1986; 322: 187–9

    Article  PubMed  CAS  Google Scholar 

  13. Kaufmann SH, Shaper JH. Association of topoisomerase II with the hepatoma cell nuclear matrix: the role of intermolecular disulfide bond formation. Exp Cell Res 1991; 192: 811–23

    Google Scholar 

  14. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993; 149: 1622–5

    PubMed  CAS  Google Scholar 

  15. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005–12

    PubMed  CAS  Google Scholar 

  16. Pienta KJ, Redman BG, Bandekar R, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401–6

    Article  PubMed  CAS  Google Scholar 

  17. Dimopoulos MA, Panopoulos C, Bamia C, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754–8

    Article  PubMed  CAS  Google Scholar 

  18. Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985; 45: 3891–7

    PubMed  CAS  Google Scholar 

  19. Dexeus F, Logothetis CJ, Samuels ML, et al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985; 69: 885–6

    PubMed  CAS  Google Scholar 

  20. Batra S, Karlsson R, Witt L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 1996; 68: 644–9

    Article  PubMed  CAS  Google Scholar 

  21. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 1992; 10: 1754–61

    PubMed  CAS  Google Scholar 

  22. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer. J Urol 1992; 147: 931–4

    PubMed  CAS  Google Scholar 

  23. Attivissimo LA, Fetten JV, Kreis W. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol 1996; 19: 581–3

    Article  PubMed  CAS  Google Scholar 

  24. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). New Engl J Med 1995; 332: 1004–14

    Article  PubMed  CAS  Google Scholar 

  25. Roytta M, Laine KM, Harkonen P. Morphological studies on the effect of taxol on cultured human prostate cancer cells. Prostate 1987; 11: 95–106

    Article  PubMed  CAS  Google Scholar 

  26. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormonerefractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457–60

    CAS  Google Scholar 

  27. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992; 52: 4433–40

    PubMed  CAS  Google Scholar 

  28. Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide and taxol on prostate cancer cell growth invitroand invivo. Urology 1996; 48: 164–70

    Article  PubMed  CAS  Google Scholar 

  29. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995; 22 Suppl. 12: 41–5

    PubMed  CAS  Google Scholar 

  30. Pienta KJ, Esper PS, Smith DC. The oral regimen of Cytoxan®, prednisone and diethylstilbestrol is an active, non-toxic treatment for patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 1997; 16: 310A

    Google Scholar 

  31. Maulard-Durdux C, Dufour B, Hennequin C, et al; Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77: 1144–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan School of Medicine, 1500 E. Medical Center Dr., 7303 GCGC, Ann Arbor, Michigan, 48109-0005, USA

    Kenneth J. Pienta, Jeffrey M. Kamradt & David C. Smith

Authors
  1. Kenneth J. Pienta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Kamradt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David C. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pienta, K.J., Kamradt, J.M. & Smith, D.C. Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer. Drugs 58 (Suppl 3), 127–131 (1999). https://doi.org/10.2165/00003495-199958003-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00017

Keywords

Search

Navigation